
CBE ID

3534

Title

30 Day All-cause Risk Standardized Mortality Odds Ratio following Transcatheter Aortic Valve Replacement (TAVR).

Endorsement Status

Endorsed

Is Under Review

No

Next Maintenance Cycle

Spring 2026

Previous Endorsement Cycle

Fall 2019

Initial Endorsement

Fri, 07/31/2020 - 10:46

Steward

American College of Cardiology

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

This measure estimates hospital risk standardized odds ratio for death from all causes within 30 days following transcatheter aortic valve replacement. The measure uses clinical data available in the STS/ACC TVT Registry for risk adjustment. For the purpose of development and testing, the measure used site-reported 30-day follow-up data contained in the STS/ACC TVT Registry.

1.7 Measure Type

Outcome

1.8 Level of Analysis

Facility

1.13 Data Dictionary

Not attached. I attest that all information will be provided where codes and/or value sets are needed (1.14a - 1.15c).

1.14 Numerator

The outcome of this measure is all-cause death within 30 days following a transcatheter aortic valve replacement (TAVR).

1.15 Denominator

The target population for the outcome is for individuals who have undergone transcatheter aortic valve replacement. For development, reassessment and reporting of this measure, we use site reported data from the STS/ACC TVT Registry.

6.1.2 Current or Planned Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

- 1) Hospitals need to meet eligibility criteria to be included in the measure.
- 2) Patients are excluded if:
 - a) They did not have a first-time TAVR in the episode of care (admission),
 - b) The TAVR was subsequent to another procedure in the Registry (other TAVR, Mitral Leaflet Clip and/or TMVR) during that admission.
 - c) The patient is readmitted for a repeat TAVR (re-admission) and the initial TAVR was performed during the rolling 3-year timeframe for the measure.
 - d) 30-day mortality status missing.

Measure Disclaimer

STS and ACC do not have a web page dedicated to the TVT Registry measure specification. Participants can access a risk model companion guide to help them understand the model. The manuscript is also a publicly available resource.

Planned Use

Public Reporting

Risk Adjustment

Statistical risk model

The measure developer is different from the measure steward

No

Steward Organization

American College of Cardiology

Steward POC email

sfitzger@acc.org